Ipilimumab: as the comparator
27 studies: what is tested is compared with it. Page 1 of 1. Open to participants first (8), then studies with results posted, then the rest; newest registration first within each.
- A Clinical Study of Ivonescimab in Combination With Cadonilimab or Ipilimumab for Advanced Renal CancerNot yet recruitingNCT07877194Phase 2Report a problem
- A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)RecruitingNCT07188896Phase 2Report a problem
- Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular CarcinomaRecruitingNCT07176650Phase 1Report a problem
- A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment for Patients with Unresectable Hepatocellular CarcinomaNot yet recruitingNCT06841185Phase 3Report a problem
- SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous MelanomaRecruitingNCT06743126Phase 3Report a problem
- A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory MelanomaRecruitingNCT06624644Phase 2/3Report a problem
- A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal MelanomaRecruitingNCT06581406Phase 2/3Report a problem
- A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male SubjectsRecruitingNCT06159101Phase 1Report a problem
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)CompletedNCT05116202Phase 1/2Results postedReport a problem
- DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural MesotheliomaCompletedNCT04334759Phase 3Results postedReport a problem
- A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid TumorsCompletedNCT03369223Phase 1/2Results postedReport a problem
- First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid TumorsTerminatedNCT03110107Phase 1/2Results postedReport a problem
- Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal MelanomaCompletedNCT03070392Phase 2Results postedReport a problem
- A Study to Test Combination Treatments in People With Advanced Renal Cell CarcinomaCompletedNCT02996110Phase 2Results postedReport a problem
- A Study to Test Combination Treatments in Participants With Advanced Gastric CancerCompletedNCT02935634Phase 2Results postedReport a problem
- Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by SurgeryActive, not recruitingNCT02506153Phase 3Results postedReport a problem
- Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV MelanomaCompletedNCT02388906Phase 3Results postedReport a problem
- Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)CompletedNCT01866319Phase 3Results postedReport a problem
- Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)CompletedNCT01844505Phase 3Results postedReport a problem
- Comparative Pharmacokinetics of SHR-8068 and Ipilimumab in Healthy Chinese MenCompletedNCT07852325Phase 1Report a problem
- A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCCActive, not recruitingNCT07000149Phase 1Report a problem
- MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural MesotheliomaActive, not recruitingNCT06097728Phase 3Report a problem
- IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal MelanomaActive, not recruitingNCT05987332Phase 2/3Report a problem
- Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical TrialSuspendedNCT05928806Phase 2Report a problem
- A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced MelanomaTerminatedNCT05926960Phase 2Report a problem
- A Study to Evaluate the Similarity in Pharmacokinetics and Safety of IBI310 and Ipilimumab(YERVOY)in Adult Healthy Chinese Male VolunteersCompletedNCT04868760Phase 1Report a problem
- Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic MelanomaCompletedNCT02278887Phase 3Report a problem